Company Overview and News

105
Why Aurora Cannabis' Acquisition Strategy Will Benefit Shareholders

2018-07-06 seekingalpha
What the benefits of its acquisitions are for the company, and why I believe they'll pay off for shareholders.
STZ.B TWMJF ACB ACBFF WEED STZ CMMDF CGC

18
With Cannabis Sales To Start Soon, Aurora Cannabis Is A Play You Need To Know

2018-06-19 seekingalpha
ACBFF is a giant with the size rivaling that of CGC, yet it comes with much less fanfare.
TWMJF ACB ACBFF WEED CMMDF CGC

35
Which Marijuana Stocks Will Benefit From Canada's Next Move?

2018-05-30 seekingalpha
Canada is likely to legalize recreational marijuana this summer, which could be a big catalyst for cannabis stocks in general, more specifically Canadian marijuana stocks.
STZ.B ACBFF STZ IIPR.PRA CMMDF CGC MT TWMJF ACB IIPR WEED APHQF MQTRF MEDFF

0
CannTrust Is A Prime Takeout Target For New Cannabis Entrants

2018-04-24 seekingalpha
Current capacity of 2,500 kg/annual is expected to reach 42,500 kg/annual once all expansions are completed.
CNTTF CMMDF

11
Did Aurora Overpay For CanniMed?

2018-03-16 seekingalpha
On March 9, Aurora Cannabis (OTCQB: ACBFF) announced that it has successfully completed its acquisition of CanniMed (OTC:CMMDF). The announcement stated that 70.66% of the outstanding shares have been tendered and all other conditions have been met under the offer. Aurora also announced that it will issue a total of approximately 50.6 million Aurora common shares and pay a total of approximately $98 million in cash for the CanniMed Shares tendered as of March 8, 2018.
ACB ACBFF APHQF CMMDF

33
Marijuana Stocks And Industry Drivers For 2018

2018-03-14 seekingalpha
I believe that this year we will see industry drivers related to capital raises and M&A.
STZ.B TWMJF ATTBF ACB ACBFF WEED STZ CMMDF MEDFF ETN ATT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...